The majority of immunotherapy approaches currently under development—including cancer vaccines, checkpoint blockade, adoptive T-cells and STING (stimulator of interferon genes) agonists—are rendered completely obsolete without functional class I HLA presentation by cancer cells. Here, STING1 is linked to cancer.